Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers
Huanyu Zhou(Pfizer (United States)), Mina Hassan‐Zahraee(Pfizer (United States)), Daniel Ziemek(Pfizer (United States)), Fabio Cataldi(Pfizer (United States)), Michael S. Vincent(Pfizer (United States)), Zachary S. Stewart(Pfizer (United States)), Mateusz Maciejewski(Pfizer (United States)), Kenneth E. Hung(Pfizer (United States)), David von Schack(Pfizer (United States)), Karen Page(Pfizer (United States)), Ying Zhang(Mayo Clinic), Xi Li(Sichuan University), Baohong Zhang(Pfizer (United States)), Julie Lee, Shanrong Zhao(Pfizer (United States)), Austin Huang(Pfizer (United States)), Yutian Zhan(Pfizer (United States)), Vivek Pradhan(Pfizer (United States)), Kenneth J. Gorelick, Shawn P. O’Neil(Pfizer (United States)), Lori Fitz(Inflammation Research Foundation)
Cited by 20
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
|Nature Metabolism|2020|775
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
|JAMA|2019|370